Menu

Biohacker Aaron Traywick Found Dead in DC Float Spa

The CEO of a biomedical startup had made headlines this year when he injected himself with an untested herpes vaccine in front of an audience.

May 1, 2018
Ashley Yeager

ISTOCK, CRUPHOTOBiohacker Aaron Traywick, who sparked controversy in February when he injected himself with an untested herpes vaccine, died on Sunday (April 29). He was 28.

The Metropolitan Police Department of the District of Columbia confirmed in an email to LiveScience that Traywick was found dead in a spa room in DC. In a statement sent to Gizmodo reporter Kristen Brown and posted on her Twitter feed, the police department says Traywick’s body has been taken to the Office of the Chief Medical Examiner for an autopsy, but no evidence exists right now to suggest a relationship between his death and the vaccine he injected into himself in February.

See “Biohacker Injects DIY Herpes Vaccine on Facebook Live

Traywick was CEO of Ascendance, a biotech startup aiming to develop gene therapy treatments and immunizations for HIV and herpes. It is also working on a gene therapy for “human augmentation designed to preserve bone mineral density and maximize muscle mass and strength,” according to the company’s website.

The therapies have their critics. Last November, the US Food and Drug Administration warned consumers to be cautious of gene therapies not under appropriate regulatory oversight, which would include those from Ascendance. Tristan Roberts, a computer programmer who ran the digital side of the company and was voluntarily injected with its HIV gene therapy, reversed course and called Traywick a “scam artist” in February, according to Gizmodo.

Roberts took a different tone after learning of Traywick’s death from a family member, VICE reports. “Aaron was a passionate visionary. He seemingly never tired as he brought people together to work on some of the most imposing challenges facing humanity,” the outlet reports Roberts said in a statement. “While many in the biohacking scene disagreed with his methods, none of them doubted his intentions. He sought nothing short of a revolution in biomedicine; the democratization of science and the opening of the flood gates for global healing.”

Traywick apparently hadn’t been in touch with his colleagues at Ascendance over the past month, according to VICE. Reportedly, the CEO and his colleagues had differing ideas about how to distribute the gene therapies as well as the direction of the company. “We all lost touch with him. It was radio silence,” Andreas Stuermer, a researcher at the company, tells VICE. “It was more than four weeks ago."

Roberts tells News2Share Traywick was found in a flotation tank at the spa. The tanks are filled with saltwater kept at human body temperature and close like a clamshell to block out noise and allow deep meditation. “He was found face down,” Roberts says.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing